About
XenImmune develops immuno-oncology therapies using a proprietary antibody-enzyme fusion protein to coat tumors with foreign glyco-antigens, triggering the immune system to recognize and reject cancer cells by mimicking organ transplant hyperacute rejection.
Explore XenImmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.